Servier
As of the edition of 20 October 2026, Servier runs 30 drugs, 15 of them marketed; it is on route A at 2 targets and on route B at 14 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 12 company names in this family.
- Biogaran: acquired in 1996; successor Les Laboratoires Servier
- Mersana Therapeutics, Inc.: acquired in 2026; successor Servier Pharmaceuticals LLC
- Day One Biopharmaceuticals, Inc.: acquired in 2026; successor Servier Pharmaceuticals LLC
Drugs by status
| Status | Count |
|---|---|
| Marketed | 15 |
| Active | 8 |
| Went quiet | 3 |
| Stopped | 4 |
| Total | 30 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Irinotecan | none listed | 2 |
| Amlodipine | none listed | 16 |
| Pegaspargase | Ended 2006 (computed from the first US licence) | 0 |
| Trifluridine | none listed | 0 |
| Tipiracil | Ends 2034 (patent) | 1 |
| Ivosidenib | Ends 2033 (patent) | 0 |
| Ivabradine | Ends 2026 (patent) | 3 |
| Perindopril | none listed | 2 |
| Pralatrexate | none listed | 3 |
| Indapamide | none listed | 1 |
| Vorasidenib | Ends 2039 (patent) | 1 |
| Calaspargase pegol | Ends 2030 (computed from the first US licence) | 0 |
| Gliclazide | none listed | 0 |
| Agomelatine | none listed | 0 |
| Tovorafenib | Ends 2031 (patent) | 6 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 2 targets, route B at 14 targets.
All 16 rows on route A or B
In the product16 company-target rows on route A or B; 13 are not shown here, and no score is.
See all 16 targets where Servier needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 16 trials led
- Lungs and airways: 6 trials led
- Digestive system: 4 trials led